Zacks Investment Research on MSN2d
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...
The Pharma Letter1d
Russia plans to increase procurements of rare disease drugs
Russia plans to increase procurements of drugs against rare diseases despite the current tough business environment and ...
PMLive2d
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
Healio5d
European Medicines Agency recommends ‘landmark’ gene therapy for epidermolysis bullosa
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Vyjuvek for the ...
Nasdaq5d
Krystal Biotech, Inc. Welcomes Positive EMA Recommendation for VYJUVEK® Approval in Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for VYJUVEK® (beremagene geperpavec-svdt ...
The Business Journals15d
Krystal Biotech shares rise 20% following earnings call
The company expects to launch its product, Vyjuvek, in the EU and Japan in 2025. STORY HIGHLIGHTS Krystal Biotech's stock rose 20% after earnings call. Vyjuvek generated $290.5 million in annual ...